Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL ISIN · CA57384M1077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2023-12-18 Regulatory Filings
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification by the CEO of Marvel Biosciences Corp. regarding the interim financial report and interim MD&A for the period ended October 31, 2023. It is a Venture Issuer Basic Certificate under Form 52-109FV2, which certifies the review and fair presentation of the interim filings but does not contain the actual financial data or the interim report itself. The document is short (2958 characters) and primarily an officer certification letter. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself. Therefore, the correct classification is Regulatory Filings (RNS).
2023-12-18 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) and dated December 18, 2023. It references unaudited condensed interim consolidated financial statements for the three months ended October 31, 2023, and the audited consolidated financial statements for the year ended July 31, 2023. The content includes detailed discussion of business strategy, product development, forward-looking statements, and financial reporting standards (IFRS). The length is substantial (15,000 characters), and the document contains substantive financial and operational analysis rather than just an announcement or certification. This matches the definition of a Management Reports (MDA) filing, which provides management's detailed explanation of financial results, business trends, and outlook. It is not an Annual Report (10-K) or Interim Report (IR) because it is specifically an MD&A accompanying interim financials, and the text is focused on management's discussion rather than full financial statements. Therefore, the correct classification is MDA with high confidence.
2023-12-18 English
Notice of meeting - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of Annual and Special Meeting of Shareholders for Marvel Biosciences Corp. It outlines the agenda for the meeting, including receiving audited financial statements, electing directors, appointing auditors, and approving stock option and equity incentive plans. It references the Management Information Circular as accompanying material but does not contain the circular itself or detailed financial data. The document is primarily a meeting notice and proxy solicitation, not the actual annual report or financial statements. The length is 4506 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of Proxy Solicitation & Information Statement (PSI), as it is a notice and proxy form related to the shareholder meeting and voting.
2023-12-15 English
Management information circular - English.pdf
Board/Management Information Classification · 95% confidence The document is titled 'NOTICE OF MEETING AND MANAGEMENT INFORMATION CIRCULAR' for the Annual and Special Meeting of Shareholders of Marvel Biosciences Corp. It includes detailed proxy solicitation information, meeting agenda items such as election of directors, appointment of auditors, and approval of stock option plans. The document is dated December 4, 2023, and the meeting is scheduled for January 9, 2024. The content is typical of a Management Information Circular, which is a proxy statement providing shareholders with information to vote on corporate matters at the AGM. It is not the actual Annual Report or financial statements, but rather a detailed proxy solicitation and management information document. Therefore, the appropriate classification is 'MANG' (Board/Management Information), as it relates to management and board matters and proxy solicitation for the shareholder meeting.
2023-12-15 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document text contains a 'Form of Proxy' for an Annual and Special Meeting scheduled on January 9, 2024. It includes details about appointing proxies, voting on directors, auditors, remuneration, and special resolutions. This type of document is typically sent to shareholders to provide information and solicit votes for the upcoming meeting. It is not a report of the meeting itself, nor does it contain financial statements or management discussion. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is sufficient and the content matches the description of PSI filings.
2023-12-15 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form of Proxy for an Annual and Special Meeting scheduled for January 9, 2024. It includes instructions for appointing a proxyholder to vote on behalf of shareholders on various matters such as election of directors, appointment of auditors, and approval of stock option and equity incentive plans. The document is primarily a solicitation for proxy votes and contains no financial statements or detailed financial analysis. It is related to the governance and voting process for the company's annual meeting rather than the meeting materials or results themselves. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length (5642 characters) supports it being a full proxy form rather than a brief announcement or a full report.
2023-12-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.